| Lupin’s forays into the burgeoning Neuro Psychiatry and Oncology segments are driven by this division. Citistar, Dayo OD and Lovax were the recent launches in the neuropsychiatry segment. These brands fall under the high growth therapeutic segments like epilepsy, stroke and migraine. Domestic therapeutic market of CNS ailments is estimated to be Rs.17,590
mn growing at 17% and the Indian Oncology market stands at an estimated Rs.1,900
mn. Through this division the company has also ventured into Oncology which is the segment of tomorrow. Today, it is estimated that not more than 10-15% of people actually go for treatment of cancer as it is perceived to be expensive. But with the growing infrastructure of insurance in the country and also the fact that people themselves are opting for long- term insurance plans, the people of tomorrow will be able to afford cancer treatment. Today also, the cure of cancer is just 35%. So the maximum amount of research globally is happening in oncology. The pipeline of new products is richest in oncology.
Key Products : MindVision
|
Product |
Therapeutic Segment |
Product Rank in in the relevant segment |
|
Stalopam |
Escitalopram |
2 |
|
Placidox |
Diazepam |
3 |
|
Arzu |
Aripiprazole |
3 |
|
Fibril |
Bulk Producers |
5 |
|
Dulot |
Duloxetine |
6 |
|
Citistar |
Citocholine |
6 |
| 
